What's Happening?
Kelun-Biotech has presented the first-in-human study results of its novel B7-H3 antibody-drug conjugate (ADC) SKB500 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The study involved 192 patients with advanced solid
tumors, including small cell lung cancer (SCLC) and esophageal squamous cell carcinoma (ESCC). SKB500 demonstrated significant antitumor activity, with an objective response rate of 42.7% and a disease control rate of 83.9% among patients treated at 12 mg/kg. The study also highlighted a favorable safety profile, with a lower incidence of severe treatment-related adverse events in the 12 mg/kg group compared to the 16 mg/kg group.
Why It's Important?
The promising results of SKB500 could represent a significant advancement in the treatment of various solid tumors, particularly for patients with limited treatment options. The high response rates observed in the study suggest that SKB500 could become a valuable therapeutic option for cancers such as SCLC, which is known for its aggressive nature and limited later-line treatments. The favorable safety profile further supports its potential use in clinical settings. This development underscores the importance of innovative therapies in oncology and the potential of ADCs to provide targeted treatment with reduced side effects.
What's Next?
Kelun-Biotech plans to continue the clinical development of SKB500, with further trials to validate its efficacy and safety across different tumor types. The company may explore combination therapies with immunotherapy or chemotherapy to enhance treatment outcomes. Regulatory submissions for SKB500 could follow, depending on the results of ongoing and future studies. The oncology community will be closely monitoring the progress of SKB500, as its success could pave the way for new treatment paradigms in cancer therapy.
